June 2017, Vol 8, No 3

Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC.
Read Article

National Harbor, MD—A higher readmission rate after surgery had a significant association with improved survival for patients with ovarian cancer, according to 2 studies reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row.
Read Article

National Harbor, MD—A randomized clinical trial of olaparib strengthened the PARP (poly ADP-ribose polymerase) inhibitor’s role as maintenance therapy for patients with ovarian cancer and BRCA mutation, demonstrating dramatic improvement in progression-­free survival (PFS) versus placebo.
Read Article

National Harbor, MD—Patients with recurrent metastatic cervical cancer surpassed all historical standards for 1-year survival when treated with an investigational immunotherapy targeting human papillomavirus (HPV) infection.
Read Article

National Harbor, MD—Patients with relapsed high-grade ovarian cancer with BRCA mutation derived the greatest benefit from the poly ADP-­ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article

Orlando, FL—Prophylaxis with letermovir beginning after hematopoietic-­cell transplantation (HCT) and lasting through 100 days reduced the risk for clinically significant cytomegalovirus (CMV) infection. Furthermore, letermovir was associated with lower all-cause mortality compared with placebo, reported Francisco M. Marty, MD, Associate Professor of Medicine, Harvard Medical School, Boston, at the 2017 BMT Tandem Meetings.
Read Article

Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium.
Read Article

Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizu­mab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified.
Read Article

San Antonio, TX—Concentrations of tumor-infiltrating lymphocytes (TILs) had significant but variable associations with survival in breast cancer, according to 2 large retrospective studies of pathology specimens reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article

Page 1 of 2